Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
Glioblastoma | D005909 | EFO_0000515 | — | 1 | 1 | — | — | — | 1 |
Fallopian tube neoplasms | D005185 | — | — | 1 | 1 | — | — | — | 1 |
Ovarian epithelial carcinoma | D000077216 | — | — | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 2 | — | — | — | — | 2 |
Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
Drug common name | RALIMETINIB |
INN | ralimetinib |
Description | Ralimetinib (LY2228820) is a small molecule experimental cancer drug in development by Eli Lilly. Although originally thought to be a p38 mitogen-activated protein kinase (MAPK) inhibitor, it has since been reported that it acts instead as an epidermal growth factor receptor (EGFR) inhibitor.
|
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors; MEK (MAPK kinase) inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(C)(C)Cn1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)nc21 |
PDB | — |
CAS-ID | 862505-00-8 |
RxCUI | — |
ChEMBL ID | CHEMBL2364626 |
ChEBI ID | — |
PubChem CID | 11539025 |
DrugBank | — |
UNII ID | 73I34XW4HD (ChemIDplus, GSRS) |